Study guide
9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension
USMLE Step 2 CK Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Human Development & Well-Patient Care
1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening
2 Chapter 2: Immune System & Immunologic Disorders
2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles
3 Chapter 3: Blood & Lymphoreticular System
3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders
4 Chapter 4: Behavioral Health & Psychiatric Disorders
4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology
5 Chapter 5: Nervous System & Special Senses
5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies
6 Chapter 6: Musculoskeletal System & Dermatology
6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders
7 Chapter 7: Cardiovascular System
7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease
8 Chapter 8: Respiratory System
8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases
9 Chapter 9: Gastrointestinal System
9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis
10 Chapter 10: Renal, Urinary & Reproductive Systems
10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease
11 Chapter 11: Pregnancy, Childbirth & Puerperium
11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management
12 Chapter 12: Endocrine System
12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology
13 Chapter 13: Multisystem Processes & Critical Care
13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens
14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation
14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine
15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice
15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions
9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension
Key Takeaways Explain This Topic AI
Serum Ascites-Albumin Gradient (SAAG) >=1.1 g/dL indicates portal hypertension (cirrhosis, heart failure, Budd-Chiari), whereas SAAG <1.1 g/dL points to non-portal etiologies (peritoneal carcinomatosis, TB, nephrotic syndrome).
Spontaneous Bacterial Peritonitis (SBP) is diagnosed by paracentesis showing absolute neutrophil count (ANC) >=250/mm^3 in ascites fluid; empiric treatment is IV cefotaxime or ceftriaxone.
Primary biliary cholangitis (PBC) is characterized by anti-mitochondrial antibodies (AMA positive >95%) targeting intrahepatic interlobular bile ducts, treated with ursodeoxycholic acid (UDCA).
Wilson disease features autosomal recessive ATP7B gene mutation causing impaired biliary copper excretion, decreased serum ceruloplasmin (<20 mg/dL), elevated 24-hour urinary copper (>100 mcg/24h), and Kayser-Fleischer rings on slit-lamp examination.
Screening for hepatocellular carcinoma (HCC) in patients with cirrhosis requires abdominal ultrasound with or without serum alpha-fetoprotein (AFP) every 6 months.
Last updated: July 2026
9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension
High-Yield Overview: Hepatic pathology centers on evaluating parenchymal liver injury, cholestatic patterns, metabolic liver diseases, and the systemic consequences of cirrhosis. Management revolves around risk-stratifying ascites via the SAAG score, identifying spontaneous bacterial peritonitis, preventing variceal hemorrhage, and maintaining strict semi-annual HCC surveillance.
- Viral Hepatitis & Hereditary Metabolic Liver Diseases
- Viral Hepatitis Summary
- Virus Transmission Chronicity Risk Key Diagnostic Markers Clinical Highlights / Management
- HAV Fecal-oral 0% (Always acute) Anti-HAV IgM Self-limited; post-exposure prophylaxis with vaccine or IG
HBV Parenteral, sexual, perinatal 90% in neonates; 5-10% in adults HBsAg (active infection), Anti-HBc IgM (window phase), HBV DNA First-line treatment: Tenofovir or Entecavir; Peg-IFN
HCV Parenteral (IVDU, transfusions) 75-85% chronic Anti-HCV Ab, HCV RNA PCR Curative treatment with oral Direct-Acting Antivirals (DAAs)
HDV Parenteral Requires HBsAg coat Anti-HDV Ab / HDV RNA Superinfection on chronic HBV markedly accelerates cirrhosis
HEV Fecal-oral (waterborne) 0% (Except transplant) Anti-HEV IgM High mortality rate ( 20% ) in pregnant women due to fulminant liver failure
Hereditary Metabolic Liver Pathology
Hereditary Hemochromatosis: Autosomal recessive HFE gene mutation (C282Y). Iron overload deposits in liver, pancreas, heart, joints, and pituitary gland ( "Bronze Diabetes" : skin hyperpigmentation, diabetes mellitus, cirrhosis, restrictive/dilated cardiomyopathy, hypogonadism, MCP joint arthropathy).
Screening: Transferrin saturation >45% and serum ferritin >200 ng/mL (female) or >300 ng/mL (male).
Treatment: Weekly therapeutic phlebotomy (target ferritin 50-100 ng/mL).
Wilson Disease (Hepatolenticular Degeneration): Autosomal recessive mutation in ATP7B (chromosome 13), impairing biliary copper excretion and ceruloplasmin binding.
Presentation: Hepatic dysfunction (cirrhosis, acute liver failure), neuropsychiatric symptoms (resting tremor, parkinsonism, dysarthria, psychosis), and Kayser-Fleischer rings (copper deposition in Descemet membrane of cornea).
Diagnostics: Decreased serum ceruloplasmin (<20 mg/dL), elevated 24-hour urinary copper excretion (>100 mcg/24h), and elevated hepatic copper on biopsy (>250 mcg/g dry weight).
Treatment: Copper chelators ( D-penicillamine , trientine) and oral zinc.
Alpha-1 Antitrypsin Deficiency: Autosomal codominant mutation in SERPINA1 (PiZZ allele). Accumulation of misfolded AAT protein in hepatocytes ( PAS-positive, diastase-resistant globules ) leads to cirrhosis and panacinar emphysema in young non-smokers.
- Autoimmune & Cholestatic Liver Disorders
- Primary Biliary Cholangitis (PBC)
Autoimmune destruction of intrahepatic small interlobular bile ducts occurring primarily in middle-aged women (9:1 female ratio).
Clinical Presentation: Severe fatigue, generalized pruritus (often preceding jaundice), hyperpigmentation, and xanthelasmas.
Diagnostics: Elevated alkaline phosphatase, elevated IgM, and highly specific Anti-Mitochondrial Antibodies (AMA positive >95%) .
Histology: Florid duct lesions with granulomatous duct destruction.
First-Line Therapy: Ursodeoxycholic acid (UDCA) slows histological progression and delays liver transplantation.
Primary Sclerosing Cholangitis (PSC)
Fibrosing inflammation and obliteration of both intrahepatic AND extrahepatic bile ducts.
Association: 80% associated with Ulcerative Colitis .
Diagnostics: p-ANCA positive. MRCP or ERCP demonstrates multifocal strictures and segmental dilations forming a "beaded" appearance .
Complications: High risk of developing cholangiocarcinoma (10-15% lifetime risk) and gallbladder carcinoma.
Ascites Evaluation & SAAG Diagnostic Algorithm
Diagnostic paracentesis is indicated for all patients with new-onset ascites or hospital admission for cirrhotic decompensation. SAAG = Serum Albumin (g/dL) − Ascitic Fluid Albumin (g/dL) \text{SAAG} = \text{Serum Albumin (g/dL)} - \text{Ascitic Fluid Albumin (g/dL)} SAAG = Serum Albumin (g/dL) − Ascitic Fluid Albumin (g/dL) Paracentesis Performed
- |
- Calculate SAAG & Total Protein
- |
- +-------------------------+-------------------------+
- | |
- SAAG >= 1.1 g/dL SAAG < 1.1 g/dL
- (Portal Hypertension) (Non-Portal Cause)
- | |
- +------+------+ +------+------+
- | | | |
- Protein Protein Peritoneal Tuberculous
- >=2.5 g/dL <2.5 g/dL Carcinomatosis Peritonitis /
- (Cardiac (Cirrhosis / / Nephrotic Pancreatitis
- Heart Failure) Budd-Chiari) Syndrome
High SAAG (>=1.1 g/dL) = Portal Hypertension Present:
Ascitic Protein <2.5 g/dL: Cirrhosis, Budd-Chiari syndrome, Sinusoidal Obstruction Syndrome.
Ascitic Protein >=2.5 g/dL: Congestive heart failure, constrictive pericarditis.
Low SAAG (<1.1 g/dL) = No Portal Hypertension:
Peritoneal carcinomatosis, tuberculous peritonitis, nephrotic syndrome, acute pancreatitis.
- Decompensated Cirrhosis Complications
- Spontaneous Bacterial Peritonitis (SBP)
Monomicrobial infection of ascitic fluid without an intra-abdominal surgical source.
Diagnostic Criteria: Paracentesis fluid Absolute Neutrophil Count (ANC) >=250/mm^3 (WBC x % neutrophils).
Treatment: Empiric IV 3rd generation cephalosporin ( Cefotaxime or Ceftriaxone ) PLUS IV Albumin (1.5 g/kg on day 1, 1.0 g/kg on day 3) to prevent hepatorenal syndrome.
Prophylaxis: Daily oral fluoroquinolone (ciprofloxacin) or TMP-SMX for secondary prevention or high-risk primary prevention (ascitic protein <1.5 g/dL).
Acute Esophageal Variceal Hemorrhage
Screening: Screening EGD for all newly diagnosed cirrhosis patients.
Primary Prophylaxis: Non-selective beta-blockers ( nadolol, propranolol ) or endoscopic band ligation (EBL).
Acute Hemorrhage Management:
Restrictive blood transfusion strategy (target hemoglobin 7–8 g/dL ).
IV Octreotide bolus and infusion (somatostatin analog to decrease splanchnic blood flow).
Prophylactic IV Ceftriaxone for 7 days (reduces re-bleeding and mortality).
Emergent upper endoscopy within 12 hours for endoscopic band ligation .
Refractory bleeding: Transjugular Intrahepatic Portosystemic Shunt (TIPS) .
Hepatic Encephalopathy
Neuropsychiatric impairment driven by systemic accumulation of neurotoxins (ammonia) due to portosystemic shunting.
Features: Flapping tremor ( asterixis ), altered sleep-wake cycle, disorientation, somnolence, fetor hepaticus.
Common Triggers: GI bleeding, infection (SBP), constipation, hypokalemia, hypovolemia, sedatives.
First-Line Therapy: Lactulose (converted by colonic bacteria to N H 4 + NH_4^+ N H 4 + , trapping ammonia in stool; titrated to 2-3 soft bowel movements/day). Second-line add-on: Rifaximin .
Hepatocellular Carcinoma (HCC) Surveillance
All patients with cirrhosis of any etiology (or chronic HBV carriers with high-risk features) require screening with abdominal ultrasound +/- serum alpha-fetoprotein (AFP) every 6 months .